[New development for targeted therapy of non-alcoholic fatty liver disease with thyroid hormone receptor beta]

Area of Science:

• Hepatology
• Endocrinology
• Metabolic Diseases

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with no approved treatments.
• Thyroid hormone receptor β (TRβ), primarily in the liver, regulates lipid metabolism.

Purpose of the Study:

• To review the therapeutic potential of TRβ agonists for NAFLD.
• To explore the mechanisms, clinical research, and drug development status of TRβ-targeted therapies.

Main Methods:

• Literature review of studies on TRβ agonists and NAFLD.
• Analysis of TRβ's role in hepatic lipid and glucose metabolism.
• Examination of clinical trial data and drug development pipelines.

Main Results:

• TRβ agonists inhibit hepatic triglyceride synthesis and cholesterol production.
• These agonists enhance hepatic cholesterol clearance and reduce lipid accumulation.
• TRβ activation improves insulin sensitivity, glucose metabolism, and inflammation.

Conclusions:

• TRβ agonists represent a promising therapeutic strategy for NAFLD.
• Targeting TRβ offers a novel approach for managing this widespread liver condition.
• Further clinical development is warranted to establish TRβ agonists as effective NAFLD treatments.